{
  "meta": {
    "title": "Acute_Kidney_Injury",
    "url": "https://brainandscalpel.vercel.app/acute-kidney-injury-cd12d7db.html",
    "scrapedAt": "2025-11-30T08:48:54.655Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Prerenal</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Renal</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Postrenal</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Atheroembolism associated</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Muddy brown cast is associated with which form of Acute kidney injury?</span></p>",
      "unique_key": "DT1295592",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295592,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Muddy brown casts</strong> are primarily indicative of <strong>acute tubular necrosis (ATN)</strong>, a <strong>renal</strong> cause of acute kidney injury (AKI). This condition results from damage to the renal tubules, often caused by <strong>ischemia</strong> (reduced blood flow) or exposure to <strong>nephrotoxic agents</strong> (such as certain medications or toxins). The presence of these casts suggests that the renal parenchyma is affected, distinguishing it from prerenal and postrenal causes.</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Prerenal:</strong> Involves conditions like hypovolemia or heart failure leading to decreased perfusion, but does not cause structural damage, hence no muddy brown casts.</li>\r\n<li><strong>C. Postrenal:</strong> Results from obstruction (e.g., kidney stones, tumors) affecting urine flow, which does not produce muddy brown casts characteristic of renal injury.</li>\r\n<li><strong>D. Atheroembolism associated:</strong> Refers to the obstruction of renal blood flow due to emboli from atherosclerotic plaques, but this condition is not linked to the formation of muddy brown casts.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109d00c2628-6b46-428a-8aad-d406fa051334.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Muddy brown casts</strong> are a key indicator of <strong>renal</strong> injury from ATN in acute kidney injury.</li>\r\n<li>Correct identification of cast types is crucial for diagnosing the specific <strong>etiology</strong> of acute kidney injury, guiding appropriate management.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Associated with low HDL</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Muehrckes line is seen</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">In HIV associated nephropathy nephrotic range proteinuria is not associated with oedema</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is correct about Nephrotic syndrome?</span></p>",
      "unique_key": "DT1295595",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295595,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Nephrotic Syndrome (NS) Features:</strong>\r\n<ul>\r\n<li><strong>Triad of symptoms:</strong> Edema, hypoalbuminemia (&lt;3.5 g/dL), and proteinuria (&gt;3.5 g/day).</li>\r\n<li><strong>Lipid Abnormalities:</strong> Often associated with <strong>high LDL</strong>, <strong>low HDL</strong>, and <strong>lipiduria</strong>.</li>\r\n<li><strong>Muehrcke's Lines:</strong> Characteristic horizontal white lines on nails due to rapid hypoalbuminemia.</li>\r\n<li><strong>HIV-Associated Nephropathy:</strong> Nephrotic range proteinuria may occur <strong>without edema</strong>, demonstrating an exception to the typical presentation.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Associated with low HDL:</strong> correct</li>\r\n<li><strong>B. Muehrcke's line is seen:</strong> correct</li>\r\n<li><strong>C. In HIV-associated nephropathy, nephrotic range proteinuria is not associated with edema:</strong> correct</li>\r\n<li><strong>All of the above are correct </strong></li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109e1ad712e-a86a-4d00-bf1a-899a6c738bd0.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>Nephrotic syndrome is defined by <strong>edema</strong>, <strong>hypoalbuminemia</strong>, and <strong>proteinuria</strong>, with significant lipid abnormalities.</li>\r\n<li>Muehrcke's lines and exceptions in HIVAN highlight the complexity of presentations in nephrotic syndrome.</li>\r\n<li>Recognizing these features is essential for accurate diagnosis and management of nephrotic syndrome in clinical practice.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial Hypocalciuric Hypercalcemia</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Dent Disease</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Gitelman disease</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Hereditary Hypophosphatemic Rickets with hypercalcemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following inherited disorder primarily affects loop of Henle?</span></p>",
      "unique_key": "DT1295596",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295596,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Familial Hypocalciuric Hypercalcemia (FHH):</strong>\r\n<ul>\r\n<li><strong>Primary Effect:</strong> Primarily affects the <strong>Loop of Henle</strong>, where calcium reabsorption is regulated.</li>\r\n<li><strong>Calcium Handling:</strong> Leads to increased serum calcium levels and decreased urinary calcium excretion.</li>\r\n<li><strong>Genetic Basis:</strong> Caused by mutations in the calcium-sensing receptor gene (CaSR).</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010967098bdf-f766-4ae8-b9b7-81837bc4e3fb.png\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B. Dent Disease:</strong> Incorrect; primarily affects proximal tubular function, not the Loop of Henle.</li>\r\n<li><strong>C. Gitelman Disease:</strong> Affects distal convoluted tubule; does not impact the Loop of Henle.</li>\r\n<li><strong>D. Hereditary Hypophosphatemic Rickets:</strong> Involves proximal tubular effects on phosphate, unrelated to the Loop of Henle.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Familial Hypocalciuric Hypercalcemia</strong> primarily affects the <strong>Loop of Henle</strong>, altering calcium balance.</li>\r\n<li>Recognizing the specific tubule affected by various genetic disorders is crucial for accurate diagnosis and management.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial Hypomagnesemia</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Bartter syndrome</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial hypercalcemia hypocalciuric</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Bartter syndrome type 3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Loss of function mutation in calcium sensing receptor of thick ascending loop of Henle is associated with which of the following syndromes?</span></p>",
      "unique_key": "DT1295597",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295597,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Familial Hypercalcemia Hypocalciuric (FHH):</strong>\r\n<ul>\r\n<li><strong>Mutation:</strong> Caused by loss-of-function mutations in the <strong>calcium-sensing receptor (CaSR)</strong> located in the thick ascending loop of Henle.</li>\r\n<li><strong>Pathophysiology:</strong> Blunts the renal response to extracellular calcium, leading to <strong>increased serum calcium</strong> and <strong>decreased urinary calcium excretion</strong>.</li>\r\n<li><strong>Regulatory Role:</strong> CaSR plays a crucial role in maintaining calcium homeostasis by regulating NaCl reabsorption through G protein-coupled signaling.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Syndromes:</strong>\r\n<ul>\r\n<li><strong>A. Familial Hypomagnesemia:</strong> Caused by mutations in CLDN16; involves magnesium reabsorption issues.</li>\r\n<li><strong>B. Bartter Syndrome:</strong> Salt-wasting renal disease with hypokalemia and metabolic alkalosis; caused by mutations in various genes affecting Na+/K+/2Cl&minus; cotransporter or potassium channels.</li>\r\n<li><strong>D. Bartter Syndrome Type 3:</strong> Similar to Bartter syndrome but specifically linked to a different gene; not associated with CaSR mutations.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Familial Hypomagnesemia:</strong> Incorrect; not related to CaSR but to CLDN16 mutations affecting magnesium.</li>\r\n<li><strong>B. Bartter Syndrome:</strong> Incorrect; although CaSR mutations may contribute, this syndrome encompasses a wider range of genetic mutations.</li>\r\n<li><strong>D. Bartter Syndrome Type 3:</strong> Incorrect; primarily associated with a mutation in a different gene (BSND) unrelated to CaSR.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Loss of function mutations</strong> in the <strong>calcium-sensing receptor</strong> are linked to <strong>Familial Hypercalcemia Hypocalciuric</strong>, affecting calcium handling in the kidneys.</li>\r\n<li>Understanding the role of CaSR and its mutations aids in distinguishing between inherited renal syndromes related to the thick ascending loop of Henle.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Basolateral Na+/CL- channel</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">TRPM6</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">TRPM7</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Apical Na/Cl- channel</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Mutation in which of the following transport channels leads to Gitelman syndrome?</span></p>",
      "unique_key": "DT1295598",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295598,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Gitelman Syndrome:</strong></li>\r\n</ul>\r\n<p><strong>Mutation Location:</strong> Caused by mutations in the <strong>apical Na/Cl- channel</strong> in the distal convoluted tubule (DCT).</p>\r\n<p><strong>Pathophysiology:</strong> This recessive salt-losing tubulopathy leads to impaired sodium and chloride reabsorption, resulting in specific biochemical abnormalities.</p>\r\n<p><strong>Clinical Features:</strong> Characterized by <strong>hypokalemia</strong>, <strong>hypomagnesemia</strong>, <strong>hypocalciuria</strong>, <strong>metabolic alkalosis</strong>, and <strong>hyperreninemic hyperaldosteronism</strong>, resembling the effects of thiazide diuretics.</p>\r\n<p><strong>Presentation:</strong> Typically presents in <strong>late childhood or young adulthood</strong> with normal growth, muscular cramps, weakness, and potential hypotension.</p>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Basolateral Na+/Cl- Channel:</strong> Incorrect; Gitelman syndrome specifically involves the apical channel, not the basolateral one.</li>\r\n<li><strong>B. TRPM6:</strong> Incorrect; while TRPM6 mutations lead to hypomagnesemia, they are not responsible for Gitelman syndrome.</li>\r\n<li><strong>C. TRPM7:</strong> Incorrect; mutations in TRPM7 are associated with different conditions and do not cause Gitelman syndrome.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Gitelman syndrome</strong> is caused by mutations in the <strong>apical Na/Cl- channel</strong>, leading to significant electrolyte imbalances.</li>\r\n<li>Recognizing this condition's features is crucial for differential diagnosis from similar syndromes, such as Bartter syndrome and Liddle syndrome.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Malignant hypertension</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Congestive heart failure</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">NSAIDs</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Cyclosporine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a cause of prerenal AKI?</span></p>",
      "unique_key": "DT1295600",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295600,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Prerenal Acute Kidney Injury (AKI):</strong></p>\r\n<p><strong>Definition:</strong> Prerenal AKI is primarily caused by conditions leading to decreased renal perfusion, affecting blood flow to the kidneys.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501091acd416b-e0ed-4898-a91c-aa39df499344.jpg\">\r\n<p><strong>Options Explained:</strong></p>\r\n<ol style=\"list-style-type: upper-alpha;\">\r\n<li><strong> Malignant Hypertension:</strong> This condition causes <strong>increased renal perfusion pressure</strong>, which can lead to kidney damage, but it is not a cause of prerenal AKI.</li>\r\n<li><strong> Congestive Heart Failure:</strong> Results in reduced cardiac output, leading to decreased renal perfusion, thus a cause of prerenal AKI.</li>\r\n<li><strong> NSAIDs:</strong> Inhibit renal prostaglandin synthesis, impairing afferent arteriole dilation, causing reduced renal perfusion and contributing to prerenal AKI.</li>\r\n<li><strong> Cyclosporine:</strong> A nephrotoxic medication that can lead to renal vasoconstriction and decrease renal blood flow, contributing to prerenal AKI.</li>\r\n</ol>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B. Congestive Heart Failure:</strong> Incorrect; it's a classic cause of prerenal AKI due to low effective circulating volume.</li>\r\n<li><strong>C. NSAIDs:</strong> Incorrect; they can impair renal blood flow by inhibiting vasodilatory prostaglandins.</li>\r\n<li><strong>D. Cyclosporine:</strong> Incorrect; it causes vasoconstriction of the renal arterioles, contributing to prerenal AKI.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Malignant hypertension</strong> does not cause prerenal AKI; instead, it can enhance renal perfusion pressure.</li>\r\n<li>Recognizing causes of prerenal AKI is essential for timely intervention and management in acute kidney injury cases.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 51,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Diabetic Cheiroarthropathy</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Nephrogenic systemic fibrosis</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Contrast Hypersensitivity</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Scleroderma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A stage IV CKD patient undergoes Gadolinium Contrast MRI study of brain for evaluation of suspected osteomyelitis. 3 months after this he presents with generalized pruritus, cutaneous papules and generalized dermal oedema along with sensation of tightening of skin. Examination reveals generalized skin thickening except face. Which of the following is most likely diagnosis?</span></p>",
      "unique_key": "DT1295602",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295602,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Nephrogenic Systemic Fibrosis (NSF):</strong>\r\n<ul>\r\n<li><strong>Association with Gadolinium:</strong> NSF has been linked to the use of gadolinium-based contrast agents in patients with advanced kidney disease, particularly after exposure to group I agents.</li>\r\n<li><strong>Clinical Presentation:</strong> Characterized by <strong>generalized pruritus</strong>, <strong>cutaneous papules</strong>, <strong>dermal edema</strong>, and <strong>skin thickening</strong> (notably sparing the face), along with a tightening sensation.</li>\r\n<li><strong>Temporal Relationship:</strong> The timing of symptoms (3 months post-exposure) supports a diagnosis of NSF.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Diabetic Cheiroarthropathy:</strong> Incorrect; it does not cause generalized skin changes like those seen in NSF.</li>\r\n<li><strong>C. Contrast Hypersensitivity:</strong> Incorrect; it causes immediate reactions, not chronic skin changes.</li>\r\n<li><strong>D. Scleroderma:</strong> Incorrect; while it presents with skin changes, it typically affects the face and has systemic symptoms.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Nephrogenic Systemic Fibrosis</strong> is a serious condition linked to gadolinium use in patients with renal impairment, characterized by specific skin findings.</li>\r\n<li>Awareness of NSF is crucial in managing patients with advanced kidney disease who require imaging with gadolinium-based contrast agents.</li>\r\n</ul>\r\n<p>Current recommendations are that patients with CKD stage 3 (GFR 30&ndash;59 mL/min) should minimize exposure to gadolinium and those with CKD stages 4&ndash;5 (GFR &lt;30 mL/min) should avoid the use of gadolinium agents unless it is medically necessary.</p>\r\n ",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Vancomycin</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Acyclovir</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Aminoglycosides</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Amphotericin B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Polyuria can be a manifestation of renal toxicity of which of the following drugs?</span></p>",
      "unique_key": "DT1295604",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295604,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Amphotericin B:</strong>\r\n<ul>\r\n<li><strong>Mechanism of Toxicity:</strong> Causes <strong>renal vasoconstriction</strong> and <strong>direct tubular toxicity</strong> mediated by reactive oxygen species.</li>\r\n<li><strong>Clinical Features:</strong> Renal toxicity can lead to <strong>polyuria</strong>, <strong>hypomagnesemia</strong>, <strong>hypocalcemia</strong>, and <strong>non-gap metabolic acidosis</strong>, often dose and duration dependent.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Other Drugs:</strong>\r\n<ul>\r\n<li><strong> Vancomycin:</strong> Primarily causes <strong>tubular injury</strong> and intratubular obstruction, not specifically polyuria.</li>\r\n<li><strong> Acyclovir:</strong> Can cause <strong>tubular obstruction</strong> but is more associated with acute kidney injury via precipitation in the tubules.</li>\r\n<li><strong> Aminoglycosides:</strong> Cause <strong>tubular necrosis</strong> but typically result in <strong>nonoliguric AKI</strong> rather than polyuria.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong> Vancomycin:</strong> Incorrect; it causes tubular injury but not specifically polyuria.</li>\r\n<li><strong> Acyclovir:</strong> Incorrect; its nephrotoxicity is due to precipitation, not polyuria.</li>\r\n<li><strong> Aminoglycosides:</strong> Incorrect; they cause tubular necrosis, leading to nonoliguric AKI but not specifically polyuria.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Amphotericin B</strong> is notable for causing polyuria due to its renal toxic effects, along with other electrolyte imbalances.</li>\r\n<li>Understanding drug-induced acute kidney injury is crucial for preventing and managing complications in patients receiving nephrotoxic medications.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Tumour Lysis syndrome(TSS)</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Rhabdomyolysis</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Chemotherapy induced Thrombotic Thrombocytopenic purpura</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Malignant infiltration of kidney</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A diagnosed case of Burkitt Lymphoma is started on Induction Chemotherapy. 3 days after starting therapy he develops decreased urine output. Evaluation shows hyperkalemia, Hypocalcemia, hyperphosphatemia and hyperuricemia and raised serum urea and creatinine. Serum Creatine Phosphokinase is 150 (normal <120 U/L). The ratio of urinary uric acid to urinary creatinine is >1. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295605",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295605,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Tumor Lysis Syndrome (TLS):</strong></p>\r\n<ul>\r\n<li><strong>Definition:</strong> TLS is a life-threatening condition characterized by the rapid release of intracellular contents into the bloodstream following the destruction of a large number of malignant cells, typically after chemotherapy.</li>\r\n<li><strong>Laboratory Findings:</strong>\r\n<ul>\r\n<li><strong>Hyperuricemia:</strong> Increased uric acid levels due to the breakdown of nucleic acids from lysed tumor cells, leading to uric acid nephropathy.</li>\r\n<li><strong>Hyperkalemia:</strong> Elevated potassium levels from the release of intracellular potassium, which can lead to cardiac complications.</li>\r\n<li><strong>Hyperphosphatemia:</strong> Increased phosphate levels from the breakdown of cellular phosphate, which can cause calcium phosphate precipitation in the kidneys, leading to nephrocalcinosis.</li>\r\n<li><strong>Hypocalcemia:</strong> Resulting from the binding of calcium to increased phosphate levels, leading to a decrease in serum calcium.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Timing:</strong> TLS typically occurs <strong>1-5 days</strong> after starting chemotherapy, especially in aggressive malignancies like <strong>Burkitt lymphoma</strong>.</li>\r\n<li><strong>Urinary Findings:</strong> The ratio of urinary uric acid to creatinine being &gt;1 is a strong indicator of acute hyperuricemic nephropathy, suggesting that uric acid levels in the urine are significantly elevated relative to creatinine levels.</li>\r\n<li><strong>Risk Factors:</strong> Higher tumor burden and renal dysfunction increase the likelihood of TLS. Elevated serum lactate dehydrogenase (LDH) levels often correlate with increased risk.</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B. Rhabdomyolysis:</strong> Incorrect; while it presents with high CK levels, TLS is characterized by hyperuricemia and specific urinary findings.</li>\r\n<li><strong>C. Chemotherapy Induced Thrombotic Thrombocytopenic Purpura:</strong> Incorrect; does not explain the hyperuricemia and metabolic disturbances.</li>\r\n<li><strong>D. Malignant Infiltration of Kidney:</strong> Incorrect; does not align with the acute metabolic changes observed in TLS.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Tumor Lysis Syndrome (TLS)</strong> is a critical complication of chemotherapy, especially in aggressive lymphomas, leading to life-threatening metabolic derangements.</li>\r\n<li><strong>Early recognition and management</strong> with hydration and allopurinol are essential to prevent acute renal failure and other serious complications.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Disproportionate elevation of BUN as compared to Creatinine</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Fractional excretion of Na<1%</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Urine Osmolarity <250 mosm/kg</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a feature of Prerenal AKI?</span></p>",
      "unique_key": "DT1295610",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295610,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Prerenal Acute Kidney Injury (AKI):</strong></li>\r\n<li><strong>Definition:</strong> Prerenal AKI occurs due to decreased renal perfusion leading to decreased glomerular filtration rate (GFR).</li>\r\n<li><strong>Key Features:</strong>\r\n<ul>\r\n<li><strong>Disproportionate elevation of BUN:</strong> Commonly observed as BUN/Creatinine ratio &gt;20 due to increased urea reabsorption in states of low perfusion.</li>\r\n<li><strong>Fractional excretion of sodium (FeNa):</strong> Typically &lt;1%, indicating the kidneys are conserving sodium due to low perfusion.</li>\r\n<li><strong>Urine Osmolarity:</strong> In prerenal AKI, urine osmolarity is generally &gt;500 mosm/kg, reflecting concentrated urine due to effective renal response to volume depletion.</li>\r\n<li><strong>Feature Not Seen:</strong> A urine osmolarity &lt;250 mosm/kg would indicate renal tubular damage rather than prerenal causes.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109731dc198-479b-4e2a-bc0e-20065ae77db4.png\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Disproportionate elevation of BUN as compared to Creatinine:</strong> Incorrect; this is a hallmark of prerenal AKI.</li>\r\n<li><strong>B. Fractional excretion of Na &lt;1%:</strong> Incorrect; this finding is characteristic of prerenal AKI.</li>\r\n<li><strong>D. All of the above:</strong> Incorrect; not all options are correct as options A and B are features of prerenal AKI.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>In <strong>prerenal AKI</strong>, expect <strong>BUN elevation</strong>, <strong>low FeNa</strong>, and <strong>high urine osmolarity</strong> as the kidneys respond to perceived low perfusion.</li>\r\n<li>A urine osmolarity <strong>&lt;250 mosm/kg</strong> indicates possible intrinsic renal damage, distinguishing it from prerenal causes.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Kidney Injury Molecule-1</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Neutrophil gelatinase associated lipocalin.</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Urokinase plasminogen activator receptor</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a not Novel biomarker of Acute Kidney Injury?</span></p>",
      "unique_key": "DT1295611",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295611,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Novel Biomarkers of Acute Kidney Injury (AKI):</strong>\r\n<ul>\r\n<li><strong>Kidney Injury Molecule-1 (KIM-1):</strong>\r\n<ul>\r\n<li>Detected in urine and plasma following ischemic or nephrotoxic injuries.</li>\r\n<li>Serves as a sensitive indicator of kidney injury.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Neutrophil Gelatinase Associated Lipocalin (NGAL):</strong>\r\n<ul>\r\n<li>Upregulated during inflammation and kidney injury.</li>\r\n<li>Can be measured in plasma and urine within hours of injury.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Urokinase Plasminogen Activator Receptor (suPAR):</strong>\r\n<ul>\r\n<li>Associated with predicting the development of AKI.</li>\r\n<li>Indicates tubular injury and inflammation.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Conclusion:</strong> All the options listed are novel biomarkers associated with AKI.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Kidney Injury Molecule-1:</strong> Incorrect; it is a recognized biomarker for AKI.</li>\r\n<li><strong>B. Neutrophil gelatinase associated lipocalin:</strong> Incorrect; it is also a known biomarker of AKI.</li>\r\n<li><strong>C. Urokinase plasminogen activator receptor:</strong> Incorrect; it is identified as a biomarker predicting AKI.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>All options listed (KIM-1, NGAL, and suPAR) are <strong>novel biomarkers</strong> for <strong>acute kidney injury</strong>, indicating their clinical relevance.</li>\r\n<li>The option \"None of the above\" reflects the fact that all mentioned biomarkers are indeed associated with AKI.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Terlipressin</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Liver transplantation</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Octreotide with IV albumin</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Octreotide, Midodrine with IV albumin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is considered definite Therapy for treatment of Hepatorenal syndrome?</span></p>",
      "unique_key": "DT1295612",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295612,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Definitive Therapy for Hepatorenal Syndrome:</strong>\r\n<ul>\r\n<li><strong>Liver Transplantation:</strong>\r\n<ul>\r\n<li>The only definitive treatment that can reverse hepatorenal syndrome (HRS).</li>\r\n<li>Addresses the underlying liver dysfunction causing renal impairment.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management Overview:</strong>\r\n<ul>\r\n<li>Rule out peritonitis through ascitic fluid culture.</li>\r\n<li>Administer albumin to help prevent AKI in patients treated for spontaneous bacterial peritonitis.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Bridge Therapies:</strong>\r\n<ul>\r\n<li><strong>Terlipressin</strong> (a vasopressin analog) with albumin may help but is not definitive.</li>\r\n<li><strong>Octreotide and Midodrine</strong> (with IV albumin) serve as alternative therapies when Terlipressin is unavailable.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Terlipressin:</strong> Incorrect; it&rsquo;s a bridge therapy, not a definitive treatment.</li>\r\n<li><strong>C. Octreotide with IV albumin:</strong> Incorrect; this combination is also considered a bridge therapy.</li>\r\n<li><strong>D. Octreotide, Midodrine with IV albumin:</strong> Incorrect; while helpful, it does not constitute definitive therapy.</li>\r\n</ul>\r\n<p><strong>Must Know Additional facts:</strong></p>\r\n<p>Non-oliguric causes of renal failure include long-standing urinary tract obstruction, tubulointerstitial disease, or nephrotoxicity from cisplatin or aminoglycosides, among other causes.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Liver transplantation</strong> is the <strong>definitive therapy</strong> for <strong>hepatorenal syndrome</strong>, reversing the condition by treating liver failure.</li>\r\n<li>Bridge therapies like Terlipressin or combinations with Octreotide and Midodrine can provide temporary relief but are not curative.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Sodium polystyrene sulphonate</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin with glucose</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Sevelamer hydrochloride</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhaled beta agonist therapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not used for management of hyperkalemia in Acute kidney Injury?</span></p>",
      "unique_key": "DT1295613",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295613,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Sevelamer Hydrochloride:</strong>\r\n<ul>\r\n<li><strong>Correct Answer</strong> as it primarily functions to manage <strong>hyperphosphatemia</strong> in patients with chronic kidney disease (CKD), particularly those on dialysis.</li>\r\n<li><strong>Mechanism:</strong> Binds phosphate in the gut and prevents its absorption.</li>\r\n<li><strong>Use:</strong> Not indicated for hyperkalemia management.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Management Options for Hyperkalemia:</strong>\r\n<ul>\r\n<li><strong> Sodium Polystyrene Sulphonate:</strong>\r\n<ul>\r\n<li><strong>Mechanism:</strong> Exchanges sodium for potassium in the intestines.</li>\r\n<li><strong>Use:</strong> Effective for lowering serum potassium levels.</li>\r\n<li><strong>Notes:</strong> Typically used in cases of chronic hyperkalemia.</li>\r\n</ul>\r\n</li>\r\n<li><strong> Insulin with Glucose:</strong>\r\n<ul>\r\n<li><strong>Mechanism:</strong> Insulin facilitates the uptake of glucose and potassium into cells.</li>\r\n<li><strong>Use:</strong> Rapidly reduces serum potassium levels, especially in acute situations.</li>\r\n<li><strong>Notes:</strong> Commonly administered alongside glucose to prevent hypoglycemia.</li>\r\n</ul>\r\n</li>\r\n<li><strong> Inhaled Beta Agonist Therapy:</strong>\r\n<ul>\r\n<li><strong>Mechanism:</strong> Beta agonists stimulate beta-2 receptors, leading to potassium shift into cells.</li>\r\n<li><strong>Use:</strong> Provides a quick, temporary reduction in serum potassium levels.</li>\r\n<li><strong>Notes:</strong> Useful in emergency settings for rapid control of hyperkalemia.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Sodium Polystyrene Sulphonate:</strong> Incorrect; directly lowers potassium levels via intestinal exchange.</li>\r\n<li><strong>B. Insulin with Glucose:</strong> Incorrect; effective in rapidly decreasing serum potassium through cellular uptake.</li>\r\n<li><strong>D. Inhaled Beta Agonist Therapy:</strong> Incorrect; provides rapid, temporary relief in hyperkalemia by shifting potassium into cells.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Sevelamer hydrochloride</strong> is specifically for <strong>hyperphosphatemia</strong> and not utilized for hyperkalemia treatment.</li>\r\n<li>Management of hyperkalemia in acute kidney injury involves effective agents like sodium polystyrene sulphonate, insulin with glucose, and inhaled beta agonists, each working through different mechanisms to rapidly reduce serum potassium levels.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">ACE inhibitors</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium channel blockers</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta blockers</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Clonidine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Drug of choice for treatment of Scleroderma renal crisis?</span></p>",
      "unique_key": "DT1295614",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295614,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Scleroderma Renal Crisis:</strong>\r\n<ul>\r\n<li><strong>Definition:</strong> A severe complication of scleroderma characterized by sudden onset of renal failure, hypertension, and sometimes associated with the \"watermelon stomach\" phenomenon.</li>\r\n<li><strong>Management:</strong>\r\n<ul>\r\n<li><strong> ACE Inhibitors:</strong></li>\r\n<li><strong>Mechanism:</strong> Reduce vascular resistance and lower blood pressure, improving renal blood flow.</li>\r\n<li><strong>Use:</strong> First-line therapy in managing hypertension associated with scleroderma renal crisis.</li>\r\n<li><strong>Notes:</strong> They help in reversing renal failure and controlling blood pressure effectively.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>B. Calcium Channel Blockers:</strong> Not specifically indicated for scleroderma renal crisis; more commonly used in other forms of hypertension.</li>\r\n<li><strong>C. Beta Blockers:</strong> Not relevant for this condition, mainly used for cardiac issues rather than renal crises.</li>\r\n<li><strong>D. Clonidine:</strong> Although it can lower blood pressure, it&rsquo;s not the treatment of choice in this scenario.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>ACE inhibitors</strong> are the <strong>drug of choice</strong> for treating <strong>scleroderma renal crisis</strong>, effectively managing hypertension and improving renal function.</li>\r\n<li>Recognizing specific treatments for unique etiologies of acute kidney injury is crucial for effective management and patient outcomes.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Proton Pump Inhibitors</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Allopurinol</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Quinolones</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs are not known to cause acute tubulointerstitial nephritis?</span></p>",
      "unique_key": "DT1295622",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295622,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Acute Tubulointerstitial Nephritis (ATIN):</strong>\r\n<ul>\r\n<li><strong>Definition:</strong> A kidney condition characterized by inflammation of the renal tubules and interstitium, often due to drug exposure.</li>\r\n<li><strong>Common Causes:</strong>\r\n<ul>\r\n<li><strong>A. Proton Pump Inhibitors:</strong> Known to cause ATIN through hypersensitivity reactions.</li>\r\n<li><strong>B. Allopurinol:</strong> Associated with hypersensitivity reactions leading to ATIN.</li>\r\n<li><strong>D. Quinolones:</strong> Reported to cause allergic interstitial nephritis in some cases.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li><strong>Isoniazid :</strong>\r\n<ul>\r\n<li><strong>Reasoning:</strong> While isoniazid can cause various adverse effects, it is <strong>not typically associated</strong> with acute tubulointerstitial nephritis. Its renal effects are generally related to other mechanisms rather than direct interstitial inflammation.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250109801f28b5-9cb9-4cb9-a43b-d2605479bbd8.jpg\">\r\n<p><strong>Why Not Others:</strong></p>\r\n<ul>\r\n<li><strong>A. Proton Pump Inhibitors:</strong> Commonly linked to allergic reactions causing ATIN.</li>\r\n<li><strong>B. Allopurinol:</strong> Well-documented cause of drug-induced interstitial nephritis.</li>\r\n<li><strong>D. Quinolones:</strong> Can trigger ATIN through hypersensitivity.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Isoniazid</strong> is <strong>not known</strong> to cause <strong>acute tubulointerstitial nephritis</strong>, making it the exception among the listed drugs.</li>\r\n<li>Recognizing drug-induced renal injuries is crucial for timely diagnosis and management of acute kidney injury.</li>\r\n</ul>\r\n ",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}